Ho Joon Im
Department of Pediatric Hematology & Oncology, Asan Medical Center · Asan Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ho Joon Im as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07638332 · Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell TransplantationLucasBio · not yet recruiting · Hemorrhagic Cystitis · principal investigator
- Ph2NCT05827549 · Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic LeukemiaHo Joon Im · recruiting · Acute Lymphoid Leukemia · study chair
- Ph1/Ph2NCT02014506 · Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and AdolescentsAsan Medical Center · unknown · Haploidentical Hematopoietic Stem Cell Transplantation, Malignant Disease, Non-malignant Disease · principal investigator
- Ph2NCT01759732 · Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic AnemiaAsan Medical Center · unknown · Acquired Aplastic Anemia · principal investigator
- Ph1/Ph2NCT01509300 · HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsAsan Medical Center · unknown · Acute Leukemia, Myelodysplastic Syndrome, Solid Tumors · principal investigator
- Ph1/Ph2NCT01105273 · Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic AnemiaAsan Medical Center · completed · Aplastic Anemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 155 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- MHISSION-VTH79SM058809 · SAMHSA · VERMONT STATE DEPARTMENT OF HEALTH · fiscal years 2012Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:10 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.J Nucl Med · 2017188 citationsRCR 5.9
- Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.Eur J Nucl Med Mol Imaging · 201286 citationsRCR 3.2
- Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.Blood · 200568 citationsRCR 1.7
- Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis.J Biol Chem · 201349 citationsRCR 1.5
- Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.Biol Blood Marrow Transplant · 201035 citationsRCR 1.2
- Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation.Medicine (Baltimore) · 201635 citationsRCR 1.5
- Bovine lactoferricin-induced anti-inflammation is, in part, via up-regulation of interleukin-11 by secondary activation of STAT3 in human articular cartilage.J Biol Chem · 201323 citationsRCR 0.9
- Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.Biol Blood Marrow Transplant · 201619 citationsRCR 0.9
- Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.Lancet Haematol · 202417 citationsRCR 2.7
- 16 citationsRCR 1.3